Ownership Submission
|
FORM 3
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
OMB APPROVAL
|
|
OMB Number:3235-0104Expires:January 31, 2005Estimated average burden hours per response...0.5
|
|
|
1. Name and Address of Reporting Person *
|
|
Coll Crespo Blas
|
|
2. Date of Event Requiring Statement (Month/Day/Year)
2024-09-18
|
3. Issuer Name and Ticker or Trading Symbol
Structure Therapeutics Inc. [GPCR]
|
|
(Last)
|
(First)
|
(Middle)
|
|
C/O STRUCTURE THERAPEUTICS INC. , 601 GATEWAY BLVD., SUITE 900
|
|
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
_____ Director
|
_____ 10% Owner
|
|
_____ Officer (give title below)
|
_____ Other (specify below)
|
|
Chief Medical Officer /
|
|
5. If Amendment, Date Original Filed(Month/Day/Year)
|
(Street)
|
|
SOUTH SAN FRANCISCO
|
CA
|
94080
|
|
6. Individual or Join/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
|
|
Table I - Non-Derivative Securities Beneficially Owned
|
|
|
1.Title of Security
|
2. Amount of Securities Beneficially Owned
|
3. Ownership Form: Direct (D) or Indirect (I)
|
4. Nature of Indirect Beneficial Ownership
|
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
|
2. Date Exercisable and Expiration Date
|
3. Title and Amount of Securities Underlying Derivative Security
|
4. Conversion or Exercise Price of Derivative Security
|
5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
|
6. Nature of Indirect Beneficial Ownership
|
|
Date Exercisable
|
Expriation Date
|
Title
|
Amount or Number of Shares
|
Reporting Owners
|
Reporting Owner Name / Address
|
Relationships
|
|
Director
|
10% Owner
|
Officer
|
Other
|
Coll Crespo Blas
C/O STRUCTURE THERAPEUTICS INC.
601 GATEWAY BLVD., SUITE 900
SOUTH SAN FRANCISCO, CA94080
|
|
|
Chief Medical Officer
|
|
Signatures
|
/s/ Jun Yoon, Attorney-in-Fact
|
2024-09-19
|
|
**Signature of Reporting Person
|
Date
|
Explanation of Responses:
|
(*)
|
If the form is filed by more than one reporting person, see Instruction 5(b)(v).
|
|
(**)
|
Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
|
|
(1)
|
The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents three Ordinary Shares of the Issuer.
|
|
(2)
|
Represents restricted stock unit award granted under the Issuer's 2023 Equity Incentive Plan.
|
|
(3)
|
One-fourth of the shares vested one year after May 16, 2022 (the "Vesting Commencement Date"); the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date.
|
|
(4)
|
One-fourth of the shares vested one year after March 1, 2023 (the "Vesting Commencement Date"); the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date.
|
|
(5)
|
One-fourth of the shares vest one year after March 1, 2024 (the "Vesting Commencement Date"); the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date.
|
|
(6)
|
Each ADS is convertible at any time, at the holder's election, into three Ordinary Shares of the Issuer. The ADSs have no expiration date.
|
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient,
See Instruction 6 for procedure.Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.
